Is Clene going out of business?

Clene Inc. (CLNN) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Clene Inc. (CLNN) scores 13 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)

Five questions, kept separate

Survival - Fragile

5-8 mo of estimated runway from 2026-06-30, based on $9.7M of cash and short-term investments against $18.6M of annual burn. Adjusted shares outstanding increased 30.9% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Extreme expectations

-43.9% net-cash backing support an extreme expectations pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 3 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Debt / Equity: Negative equity (balance sheet deficit; monitor solvency)
• Interest coverage: -7.2x
• Filing event risk: Going-Concern Warning (-8 pts)
• Revenue CAGR (3Y): -24.94%
• Shares dilution YoY: 30.94% (YoY)
• Return on Assets: -113.59%
• Cash Burn Deceleration: 73.80% QoQ improvement (Rapid improvement)
• Cash Runway (years): 0.52y
• Revenue per Asset Efficiency: 464.17% QoQ (Strong monetization)
• Debt Maturity Runway: 100% long-term (Long-term focused)
• Revenue growth YoY: 233.33% (YoY) - Early-Stage Surge (low base)
• FCF margin: -9292.50% (Inv. Mode)

Read from filings through 2026-08-14.

Price as of 2026-09-07.